Rufinamide (Banzel) for Epilepsy
Rufinamide (Banzel - Eisai), a triazole derivative structurally unrelated to other marketed antiepileptic drugs (AEDs), has been approved by the FDA for treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥4 years old....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Rufinamide (Banzel) for Epilepsy
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1307
Article Code: 1307b
Date: March 9, 2009
Volume: 51
Pages: 18-20
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1307
Article Code: 1307b
Date: March 9, 2009
Volume: 51
Pages: 18-20
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)